The cellular and clinical parameters of anabolic therapy for osteoporosis

Critical Reviews in Eukaryotic Gene Expression

Volumn 13, Issue 1, 2003, Pages 25-38

  Rosen, Clifford J ^a  

^a ST JOSEPH HOSPITAL   (United States)

Author keywords

Anabolic; Insulin like growth factor; Parathyroid hormone

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; HUMAN GROWTH HORMONE; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; PLATELET DERIVED GROWTH FACTOR A; SOMATOMEDIN;

AGING; ANIMAL CELL; BONE DENSITY; BONE MINERAL; DRUG EFFECT; GENE TARGETING; HORMONE ACTION; HUMAN; HUMAN CELL; HYPERPARATHYROIDISM; LIGAND BINDING; MINERALIZATION; MUTAGENESIS; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; THYROID PARAFOLLICULAR CELL; TRANSCRIPTION REGULATION;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; DRUG THERAPY, COMBINATION; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RECEPTORS, PARATHYROID HORMONE;

ANIMALIA;

EID: 0037591085     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i1.30     Document Type: Review

References (85)

1. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, Rosen C (2002): Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 31(3):659-679, xii.
2. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995): Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333(22):1437-1443.
3. Rosen CJ, Donahue LR (1998): Insulin-like growth factors and bone: the osteoporosis connection revisited. Proc Soc Exp Biol Med 219(1):1-7.
4. Mochizuki H, Hakeda Y, Wakatsuki N, Usui N, Akashi S, Sato T, Tanaka K, Kumegawa M (1992): Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 131(3): 1075-1080.
5. Rosen CJ, Pollak M (1999): Circulating IGF-I: New perspectives for a new century. Trends Endocrinol Metab 10(4):136-141.
6. Selye H (1932): On the stimulation of new bone formation with PTH extract and irradiated ergosterol. Endocrinology 16:547-558.
7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001): Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19): 1434-1441.
8. McCarthy TL, Centrella M, Canalis E (1989): Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 124(3):1247-1253.
9. Canalis E, Centrella M, Burch W, McCarthy TL (1989): Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 83(1):60-65.
10. Linkhart TA, Mohan S (1989): Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 125(3):1484-1491.
11. Kanzawa M, Sugimoto T, Kanatani M, Chihara K (2000): Involvement of osteoprotegerin/osteoclasto-genesis inhibitory factor in the stimulation of osteodast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol 142(6):661-664.
12. Chiba S, Un-No M, Neer RM, Okada K, Serge GV, Lee K (2002): Parathyroid hormone induces interleukin-6 gene expression in bone stromal cells of young rats. J Vet Med Sci 64(7):641-664.
13. Rosen CJ, Bilezikian JP (2001): Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86(3):957-964.
14. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993): Anabolic actions of parathyroid hormone on bone. Endocr Rev 14(6):690-709.
15. Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH (2000): Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27(2):311-318.
16. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM (1998): Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 280(12):1067-1073.
17. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001): Effects of daily treatment with parathyroid hormone on bone micro-architecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16(10): 1846-1853.
18. Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M (2001): Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16(9): 1665-1673.
19. Jerome CP (1994): Anabolic effect of high doses of human parathyroid hormone (1-38) in mature intact female rats. J Bone Miner Res 9(6):933-942.
20. Lane NE, Kimmel DB, Nilsson MH, Cohen FE, Newton S, Nissenson RA, Strewler GJ (1996): Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model. J Bone Miner Res 11(5):614-625.
21. Brommage R, Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP (1999): Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84(10): 3757-3763.
22. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH (2000): Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11(10):871-880.
23. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM (2001): Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16(1):157-165.
24. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001): Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28(2):150-159.
25. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R (2002): Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17(5):808-816.
26. Shen V, Dempster DW, Birchman R, Xu R, Lindsay R (1993): Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest 91(6):2479-2487.
27. Zeng G, Cole H, Smith S, Bryant H, Sato M (1998): Bone effects in mice of ovariectomy and recombinant human PTH 1-34 are highly strain dependent. Bone 23(S):448.
28. Schwietert HR, Groen EW, Sollie FA, Jonkman JH (1997): Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 61(3):360-376.
29. Fraher L, Hodsman AB, Steer B, Freeman D (1993): A comparison of the pharmacokinetics of PTH in healthy young and osteoporotic subjects. J Bone Miner Res 8S:253.
30. Henry JG, Mitnick M, Dann PR, Stewart AF (1997): Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab 82(3):900-906.
31. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003): The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18(1):9-17.
32. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998): Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102(8):1627-1633.
33. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003): Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18(3):539-543.
34. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE (2003): Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14(1):77-81.
35. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM (1994): Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331(24):1618-1623.
36. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003): Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88(3):1150-1156.
37. Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP (1999): On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84(5):1562-1566.
38. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (2000): Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 15(5):944-951.
39. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000): Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85(9):3069-3076.
40. Chorev M (2002): Parathyroid hormone 1 receptor: insights into structure and function. Receptors Channels 8(3-4):219-242.
41. Isogai Y, Akatsu T, Ishizuya T, Yamaguchi A, Hori M, Takahashi N, Suda T (1996): Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res 11(10):1384-1393.
42. Schiller PC, D'Ippolito G, Roos BA, Howard GA (1999): Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment. J Bone Miner Res 14(9):1504-1512.
43. Pearman AT, Chou WY, Bergman KD, Pulumati MR, Partridge NC (1996): Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE. J Biol Chem 271(41):25715-25721.
44. Zajac JD, Kearns AK, Skurat RM, Kronenberg HM, Bringhurst FR (1992): Regulation of gene transcription and proliferation by parathyroid hormone is blocked in mutant osteoblastic cells resistant to cyclic AMP. Mol Cell Endocrinol 87(1-3): 69-77.
45. Hilliker S, Wergedal JE, Gruber HE, Bettica P, Baylink DJ (1996): Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo. Bone 19(5):469-477.
46. Hock JM, Krishnan V, Onyia JE, Bidwell JP, Milas J, Stanislaus D (2001): Osteoblast apoptosis and bone turnover. J Bone Miner Res 16(6):975-984.
47. Watson P, Lazowski D, Han V, Fraher L, Steer B, Hodsman A (1995): Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 16(3):357-365.
48. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999): Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104(4):439-446.
49. Fujita T, Fukuyama R, Izumo N, Hirai T, Meguro T, Nakamuta H, Koida M (2001): Transactivation of core binding factor alpha1 as a basic mechanism to trigger parathyroid hormone-induced osteogenesis. Jpn J Pharmacol 86(4):405-416.
50. Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, Ducy P, Geiser AG (2003): Parathyroid hormone bone anabolic action requires cbfa1/runx2-dependent signaling. Mol Endocrinol 17(3):423-435.
51. Porte D, Tuckermann J, Becker M, Baumann B, Teurich S, Higgins T, Owen MJ, Schorpp-Kistner M, Angel P (1999): Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene 18(3): 667-678.
52. Hock JM, Gera I (1992): Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7(1):65-72.
53. Tintut Y, Parhami F, Le V, Karsenty G, Demer LL (1999): Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem 274(41):28875-28879.
54. Bidwell JP, Alvarez M, Feister H, Onyia J, Hock J (1998): Nuclear matrix proteins and osteoblast gene expression. J Bone Miner Res 13(2):155-167.
55. Lotinun S, Sibonga JD, Turner RT (2002): Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17(1):29-36.
56. Dobnig H, Turner RT (1997): The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138(11): 4607-4612.
57. Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE (2001): Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. J Cell Biochem 84(1):1-11.
58. Lee SK, Lorenzo JA (1999): Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140(8):3552-3561.
59. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001): Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142(9):4047-4054.
60. Locklin R, Khosla, S, Turner, RT, Riggs, LB (2003): Mediators of the bisphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (March) (in press).
61. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ (2000): In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15(5):863-871.
62. Li NH, Ouchi Y, Okamoto Y, Masuyama A, Kaneki M, Futami A, Hosoi T, Nakamura T, Orimo H (1991): Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cells. Biochem Biophys Res Commun 179(1):236-242.
63. Greenfield EM, Horowitz MC, Lavish SA (1996): Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J Biol Chem 271(18): 10984-10989.
64. Grey A, Mitnick MA, Masiukiewicz U, Sun BH, Rudikoff S, Jilka RL, Manolagas SC, Insogna K (1999): A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 140(10):4683-4690.
65. Hayden JM, Mohan S, Baylink DJ (1995): The insulin-like growth factor system and the coupling of formation to resorption. Bone 17(2 Suppl):93S-98S.
66. McCarthy TL, Ji C, Centrella M (2000): Links among growth factors, hormones, and nuclear factors with essential roles in bone formation. Crit Rev Oral Biol Med 11(4):409-422.
67. Le Roith D, Parrizas M, Blakesley VA (1997): The insulin-like growth factor-I receptor and apoptosis. Implications for the aging progress. Endocrine 7(1):103-105.
68. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000): The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215-244.
69. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ (2002): IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87(9):4273-4279.
70. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP (2002): Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17(9):1570-1578.
71. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S (2001): Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142(10):4349-4356.
72. Shinar DM, Endo N, Halperin D, Rodan GA, Weinreb M (1993): Differential expression of insulin-like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology 132(3):1158-1167.
73. McCarthy TL, Thomas MJ, Centrella M, Rotwein P (1995): Regulation of insulin-like growth factor I transcription by cyclic adenosine 3′,5′-monophosphate (cAMP) in fetal rat bone cells through an element within exon 1: protein kinase A-dependent control without a consensus AMP response element. Endocrinology 136(9):3901-3908.
74. Billiard J, Grewal SS, Lukaesko L, Stork PJ, Rotwein P (2001): Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts: dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta. J Biol Chem 276(33):31238-31246.
75. Billiard J, Umayahara Y, Wiren K, Centrella M, McCarthy TL, Rotwein P (2001): Regulated nuclear-cytoplasmic localization of CCAAT/enhancer-binding protein delta in osteoblasts. J Biol Chem 276(18): 15354-15361.
76. McCarthy TL, Ji C, Shu H, Casinghino S, Crothers K, Rotwein P, Centrella M (1997): 17beta-estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures. J Biol Chem 272(29):18132-18139.
77. Chen X, Dai JC, Greenfield EM (2002): Termination of immediate-early gene expression after stimulation by parathyroid hormone or isoproterenol. Am J Physiol Cell Physiol 283(5):C1432-C1440.
78. Lin FT, Daaka Y, Lefkowitz RJ (1998): beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor. J Biol Chem 273(48):31640-31643.
79. Dalle S, Ricketts W, Imamura T, Vollenweider P, Olefsky JM (2001): Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J Biol Chem 276(19):15688-15695.
80. Okimoto N, Tsurukami H, Okazaki Y, Nishida S, Sakai A, Ohnishi H, Hori M, Yasukawa K, Nakamura T (1998): Effects of a weekly injection of human parathyroid hormone (1-34) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats. Bone 22(5):523-531.
81. Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M (1999): Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 9(4):296-306.
82. FDA (7/2001): Endocrinologic and metabolic advisory committee meetings, www.fda.gov/cder/audiences/a;cspage/endocrinologicmeetings1.htm ed.
83. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003): Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88(2):569-575.
84. Stewart AF, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, Broadus AE (1988): Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest 81(2):596-600.
85. Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000): Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15(8):1517-1525.